Press release content from Globe Newswire. The AP news staff was not involved in its creation.
GT Gain Therapeutics SA Announces Funding from the Swiss Innovation Agency Supporting a 3-year ...
Gain TherapeuticsDecember 15, 2020 GMT
- Researchers will further develop the Site-directed Enzyme Enhancement Therapy (SEE-Tx) ™
technology for the treatment of rare genetic and neurodegenerative diseases
- The collaborative agreement unites resources from the Institute for Research in Biomedicine (IRB)-USI;
Neurocentro - Ente Ospedaliero Cantonale (EOC) & GT GAIN Therapeutics, SA
LUGANO, Switzerland, Dec. 15, 2020 (GLOBE NEWSWIRE) -- GT Gain Therapeutics SA (“Gain”), a subsidiary of Gain Therapeutics, Inc., a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, along with the Institute for Research in Biomedicine (IRB, affiliated to USI Università della Svizzera Italiana) and the Neurocentro announced today that Innosuisse, the Swiss Innovation Agency, has agreed to support the CHF 1.5M project by funding approximately CHF 850,000 to leverage these world class research organizations and promote continued innovation in the area of CNS diseases. The remaining support will come from Gain to cover the cost of related headcount expenses being dedicated to the project. The award specifically supports further investigation of the mechanisms of action of Gain’s proprietary STAR small molecule therapeutic candidates on lysosomal dysfunction and prion-like transmission of toxic forms of protein aggregates associated with neurodegenerative diseases.